Cargando…
Novel therapeutic strategy for melanoma based on albendazole and the CDK4/6 inhibitor palbociclib
Although an increasing number of patients benefit from immunotherapy and targeted therapies, melanoma remains incurable with increasing incidence. Drug repositioning and repurposing is an alternative strategy to discover and develop novel anticancer drugs or combined therapeutic regimens. In this st...
Autores principales: | Zhu, Lin, Yang, Qin, Hu, Rong, Li, Yanan, Peng, Yuanliang, Liu, Hong, Ye, Mao, Zhang, Bin, Zhang, Peihe, Liu-Smith, Feng, Li, Hui, Liu, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983746/ https://www.ncbi.nlm.nih.gov/pubmed/35383224 http://dx.doi.org/10.1038/s41598-022-09592-0 |
Ejemplares similares
-
Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
por: van Aken, Evert S. M., et al.
Publicado: (2021) -
Severe Cellular Immunodeficiency Triggered by the CDK4/6 Inhibitor Palbociclib
por: Guillaume, Zoé, et al.
Publicado: (2020) -
P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib
por: Li, Paiyun, et al.
Publicado: (2019) -
CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation
por: Hou, Yi-Bo, et al.
Publicado: (2019) -
Analysis of the selection of CDK4/6 inhibitors based on experience using palbociclib
por: Kikuchi, Mariko, et al.
Publicado: (2019)